Thomas K Equels bought $2K of AIM stock

Thomas K Equels, CEO & President of AIM ImmunoTech Inc. (AIM), bought 12,751 shares of AIM stock worth $2K, per an SEC Form 4 filed Nov 9, 2026.

It was an open-market purchase.

The trade happened on Nov 6, 2026, 3 days before it was made public.

AIM has moved +4.4% since the trade date, from $0.15 to $0.16 (Nov 9, 2026 close).